DelveInsight’s “Vascular Malformations Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of Vascular Malformations, historical and forecasted epidemiology, as well as Vascular Malformations market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Get a Free sample for the Vascular Malformations Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/report-store/vascular-malformations-market
Some of the Key Facts of the Vascular Malformations Market Report:
- Vascular malformations are rare, with some subtypes found in less than 1% of the population, and the market in the 7MM is expected to witness a major change during the study period, 2022–2036.
- VIJOICE (alpelisib) is currently the only FDA-approved therapy for vascular malformations associated with PIK3CA-related Overgrowth Spectrum (PROS), making it the sole approved treatment addressing the underlying disease biology of PROS-related malformations.
- According to Loose et al. (2024), around 2–4% of newborns in Germany suffer from congenital vascular malformation, while Reynolds et al. (2023) identified a PROS prevalence of 1:22,313 live births in Italy’s Piedmont Region, with molecularly positive PROS at 1:27,519.
- Orphanet estimates the overall prevalence of cerebral cavernous malformations at 1 in 200 to 1 in 1,000 individuals, while NORD estimates lymphatic malformation prevalence at approximately 1 in 4,000 live births.
- In November 2025, Kaken Pharmaceutical announced Phase III results for KP-001 (serabelisib) in Japanese patients with refractory vascular malformations, with plans to file for marketing authorization in fiscal year 2026 based on the ongoing long-term administration study.
- In January 2026, Protara Therapeutics announced that the FDA granted both Breakthrough Therapy and Fast Track designations to TARA-002 for pediatric patients with macrocystic and mixed cystic lymphatic malformations, following positive November 2025 interim Phase II STARBORN-1 results.
- In November 2025, Neurelis presented new Phase I data on NRL-1049 in cerebral cavernous malformation at the Alliance to Cure Cavernous Malformation’s 21st International Scientific & Clinical Meeting.
- Key Vascular Malformations Companies: Kaken Pharmaceutical (ARTham Therapeutics), Protara Therapeutics, Neurelis, Relay Therapeutics, OnKure Therapeutics, and others.
- With upcoming therapies advancing through the pipeline, the market size is expected to increase as these candidates address the substantial unmet need left by limited current treatment options.
Vascular Malformations Overview
Vascular malformations are categorized based on the type of vessels involved and blood flow characteristics, including capillary malformations (port-wine stains), slow-flow venous and lymphatic malformations, fast-flow arteriovenous malformations and fistulas, and congenital mixed syndromes such as Klippel-Trenaunay syndrome. They arise from abnormal growth of a single vessel type or a combination of vessel types and can range from harmless to life-threatening depending on the vessels involved. Mutations in the RAS/MAPK and PI3K/AKT signaling pathways have been implicated in the pathophysiology of most vascular malformations, raising the possibility that cancer-targeting inhibitors could be repurposed for this indication. Because there is no cure for most vascular malformations, treatment focuses on minimizing symptoms through minimally invasive techniques such as embolization, laser therapy, and sclerotherapy.
To know in detail about the Vascular Malformations market outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Vascular Malformations Market Forecast
Vascular Malformations Epidemiology
The epidemiology section of the report provides insights into the historical, current, and forecasted epidemiology trends across the seven major markets from 2022 to 2036. It draws on numerous studies and the views of key opinion leaders to explain current and forecasted trends, and it also details the diagnosed patient pool along with the assumptions used to project future trends.
Venous malformations remain the most common subtype and contribute significantly to overall disease burden, and diagnostic confusion between venous malformations and hemangiomas continues to complicate accurate identification and treatment planning across the 7MM.
Download the report to understand which factors are driving Vascular Malformations epidemiology trends @ Vascular Malformations Epidemiology Forecast
Vascular Malformations Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on how quickly the therapies used for Vascular Malformations — whether recently introduced or expected to launch during the study period, 2022–2036 — are being adopted, covering market uptake by drug, patient uptake by therapy type, and sales figures for each product.
The report’s pipeline coverage tracks therapeutic candidates in Phase II and Phase III development. KP-001/ART-001 (Kaken Pharmaceutical/ARTham Therapeutics) is an orally available PI3Kα inhibitor in Phase III trials in Japan for refractory slow-flow vascular malformations, having completed Phase I in the US and now consulting with the FDA on Phase III plans. TARA-002 (Protara Therapeutics) is a Phase II investigational cell therapy for lymphatic malformations, holding both US Rare Pediatric Disease designation and European orphan drug designation. NRL-1049 (Neurelis) is a Phase I small-molecule ROCK inhibitor designed to reduce new lesion accumulation and alleviate neurological symptoms in cerebral cavernous malformations. The report also details collaborations, acquisitions, mergers, licensing arrangements, and patent activity relevant to these emerging therapies.
Vascular Malformations Key Companies
- Kaken Pharmaceutical (ARTham Therapeutics)
- Protara Therapeutics
- Neurelis
- Relay Therapeutics
- OnKure Therapeutics
- and others
Discover more about the therapies positioned to shape the Vascular Malformations treatment landscape in the full report @ https://www.delveinsight.com/sample-request/vascular-malformations-market
Vascular Malformations Market Drivers
- Rising disease awareness and improved understanding of disease pathology among healthcare professionals and patients are contributing to earlier diagnosis and better disease management.
- The increasing prevalence of vascular malformations across the 7MM, with venous malformations remaining the most common subtype, continues to expand the overall disease burden and addressable patient population.
- Growing understanding of PI3K/AKT and RAS/MAPK pathway mutations is deepening insight into disease pathophysiology and supporting a growing focus on mutation-targeted therapies.
- The emergence of novel therapies such as KP-001, TARA-002, and NRL-1049 is expected to meaningfully improve the future treatment landscape and address currently unmet needs.
- Increasing adoption of minimally invasive procedures — including embolization, laser therapy, and sclerotherapy — is improving patient outcomes and reducing treatment-related complications.
Vascular Malformations Market Barriers
- VIJOICE remains the only FDA-approved therapy across all vascular malformation types, leaving a substantial unmet need for patients with non-PROS-related malformations.
- Vascular malformations frequently recur even after treatment, requiring long-term monitoring and repeated interventions, which adds to the overall disease and cost burden.
- Diagnostic challenges persist, particularly the frequent confusion between venous malformations and hemangiomas, which can delay accurate diagnosis and appropriate treatment.
Scope of the Vascular Malformations Market Report
- Study Period: 2022–2036
- Coverage: 7MM
- Key Vascular Malformations Companies: Kaken Pharmaceutical (ARTham Therapeutics), Protara Therapeutics, Neurelis, Relay Therapeutics, OnKure Therapeutics, and others
- Vascular Malformations Therapeutic Assessment: Current marketed and emerging therapies
- Vascular Malformations Market Dynamics: Market drivers and market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, market entry strategies
- Vascular Malformations Unmet Needs, KOL’s Views, Analyst’s Views, Vascular Malformations Market Access and Reimbursement
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.
Contact Information
Kanishk
